SecBot SecBot

ALPS

Alps Group Inc
Nasdaq· Services-Health Services· Inc. E9· CIK 0002025774 Healthcare & Medical Devices
$0.3280 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $0.3280
Market cap
$54.6M
Micro cap
1 year
−87.2%
from $2.56 · Oct 31
30 days
−18.0%
from $0.4000
52-week range
$0.2700–2.56
−87% from high · low Aug 19
Avg volume 20D
34.8K
Sep 28 spike 118.0K
Short interest
🔒 Subscribers only
Filing reports
4
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3
Strongest NEUTRAL Alps Group Inc filed a 6-K with proxy materials for an October 21, 2026 extraordinary general meeting…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • X Jul 31 Short interest falls 47.3% to 16.4K
  • X Aug 14 Short interest jumps 61.6% to 26.5K
  • X Aug 31 Short interest jumps 28.9% to 34.1K
  • X Sep 15 Short interest jumps 264.0% to 124.2K

Signal stack

Where each data set points today.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F
Top holderSharesValue
MILLENNIUM MANAGEMENT LLC362,233$210.1K
CITADEL ADVISORS LLC42,160$24.5K
JONES FINANCIAL COMPANIES LLLP24,950$15.1K
SUSQUEHANNA INTERNATIONAL GROUP, LLP23,531$13.6K
UBS Group AG1,635$948.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Alps Group Inc filed a 6-K with a supplement to its proxy statement, postponing the Extraordinary General Meeting from…
6-K — Impact 2/10
Oct 8, 2026 SEC
Alps Group Inc filed a 6-K with proxy materials for an October 21, 2026 extraordinary general meeting. Shareholders…
6-K — Impact 4/10
Aug 7, 2026 SEC
Alps Group Inc reported a 44% revenue increase to $4.9 million, driven by growth across cellular therapy, medical…
PRESS-RELEASE — Impact 4/10
Aug 7, 2026 Earnings
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing,

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Aug 7, 2026
Earnings
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and…
Jun 23, 2026
Press release
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO…
Jun 9, 2026
Press release
Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022
MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening…
May 19, 2026
Press release
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences…
Apr 17, 2026
Press release
Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight
Alps Group Inc (Nasdaq: ALPS) appoints former Ernst & Young Partner to its Board of Directors, strengthening governance and capital markets oversight.

SecBot reports

4 filings · 0 bullish · 0 bearish · 4 neutral
All ALPS filing & press-release reports (4)